Menu Back to Committee

Programme Co-Chairs

Susan FordaSusan Forda
Vice President, International Regulatory Affair
Eli Lilly & Company Ltd, United Kingdom

Ian HudsonIan Hudson
Chief Executive
MHRA, United Kingdom

A Message from the Co-chairs

Dear Colleagues,

We are delighted to announce that the 29th Annual DIA EuroMeeting will be held in Glasgow, on 29-31 March 2017.

Glasgow is a world-class city and a celebrated travel destination. Once termed “The city of reality”, more recently Glasgow was voted as “The friendliest city in the world”.

With certainty, global medicine development and patient care has never been more complex. We’re witnessing an evolution of science through the establishment of novel biomarkers and a better understanding of the genetic components of diseases. Still, the attrition rate for medicines in development remains high and the timelines preceding the availability of a new medicine lengthy. Meanwhile, the burden of unmet medical need within society has never been more acute. These are the realities we, in medicine development, regulation, delivery and, often as patients, face.

These complex challenges require collaboration of multiple stakeholders – regulators, clinicians, patients, payers and medicine developers – who are equally resolute to the task. Is there a better venue to host this global call for a cooperative effort than “The friendliest city in the world”?

Indeed, the 2017 DIA EuroMeeting in Glasgow represents an ideal time and setting to discuss the evolving European healthcare environment; to reflect on the outcome of recent changes such as alternative regulatory pathways; and to look ahead at emerging developments, such as how the rise of Big Data might impact medicine development, regulation, access and use.

To this end, we are truly honored to serve as the Program Co-Chairs for this important meeting. The sessions offered this year will cover a wide range of topics for pharmaceuticals, biotechnology and medical products. Planned themes include:

  • The current and potential future impacts of eHealth, mHealth and 'Big Data'
  • The effects of collaborative scientific advice involving multiple stakeholders
  • The evolution of and experience with alternative regulatory and access models
  • Meaningful clinical benefit and value frameworks
  • Operational efficacy of clinical trials and personalised medicines
In closing, mindful of the current realities, yet charged by the collective objective of improving patient care, together with our DIA colleagues, we look forward to collaborating with you during the 29th DIA EuroMeeting in Glasgow.

Program Committee

  • Salah-Dine  Chibout
    Salah-Dine Chibout Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
    Novartis Pharma AG, Switzerland
  • Jens  Grueger, PhD
    Jens Grueger, PhD Head Global Pricing & Market Access, Pharma Division
    F. Hoffmann-La Roche, Switzerland
  • Luca  Pani, MD
    Luca Pani, MD CHMP and SAWP - Member
    European Medicine Agency (EMA), United States
  • Michelle  Rohrer, PhD
    Michelle Rohrer, PhD Vice President, Global Head Regulatory Regions and Policy
    Genentech, A Member of the Roche Group , United States
  • Ad  Schuurman, MBA, MSc
    Ad Schuurman, MBA, MSc Head of the Business Contact Centre & International Affairs
    National Health Care Institute (ZIN), Netherlands
  • Sabine  Atzor, RPh
    Sabine Atzor, RPh Director Regulatory Affairs , EFPIA, Belgium
    On Secondment From F. Hoffmann-La Roche, Switzerland
  • Indranil  Bagchi, PhD, MS
    Indranil Bagchi, PhD, MS Vice President and Head, Payer Insights and Access, Patient and Health Impact
    Pfizer Inc, United States
  • Isabelle M de Zegher, MD, MSc
    Isabelle M de Zegher, MD, MSc Vice President
    PAREXEL Informatics, Belgium
  • Petra  Doerr, PharmD, PhD, RPh
    Petra Doerr, PharmD, PhD, RPh Deputy Executive Director
    Swissmedic, Switzerland
  • João  Duarte, MPharm
    João Duarte, MPharm Associate Director, Europe Regulatory Policy & Intelligence
    Takeda, United Kingdom
  • Georgy  Genov, MD
    Georgy Genov, MD Head of Signal and Incident Management
    European Medicines Agency, European Union, United Kingdom
  • Martin  Harvey Allchurch, LLM
    Martin Harvey Allchurch, LLM Principal International Affairs Officer
    European Medicines Agency, European Union, United Kingdom
  • Anthony  Humphreys, MPharm
    Anthony Humphreys, MPharm Head of Committee Secretariat Department
    European Medicines Agency, European Union , United Kingdom
  • Merete  Joergensen, MBA, MSc
    Merete Joergensen, MBA, MSc Director, Global Clinical Registry
    Novo Nordisk A/S, Denmark
  • Cordula  Landgraf, RPh
    Cordula Landgraf, RPh Head of Networking
    Swissmedic, Switzerland
  • Jordi  Llinares Garcia
    Jordi Llinares Garcia Head of Scientific and Regulatory Management
    European Medicines Agency, European Union, United Kingdom
  • Thomas  Metcalfe, MBA
    Thomas Metcalfe, MBA Strategic Innovation Leader, Pharma Development
    F. Hoffmann-La Roche, Switzerland
  • Sharon N. Olmstead
    Sharon N. Olmstead Global Head, Development and Regulatory Policy
    Novartis Pharmaceuticals Corporation, United States
  • Francesco  Pignatti, MD
    Francesco Pignatti, MD Head of Oncology, Haematology, Diagnostics
    European Medicines Agency (EMA), United Kingdom
  • Holger Maria Rohde, PhD, MBA, MSc
    Holger Maria Rohde, PhD, MBA, MSc Director Regulatory Project Management
    Merck KGaA, Germany
  • Bettina  Ryll
    Bettina Ryll Founder
    Melanoma Patient Network Europe, Sweden
  • Claudine  Sapède, PharmD, MSc
    Claudine Sapède, PharmD, MSc Global HTA & Payment Policy Lead
    F. Hoffmann-La Roche, Switzerland
  • Fergus  Sweeney, PhD
    Fergus Sweeney, PhD Head of Inspections and Human Medicines Pharmacovigilance (Division)
    European Medicines Agency, European Union, United Kingdom
Load More